Unmanipulated autologous bone marrow transplant (ABMT) offers patients with chronic myelogenous leukemia (CML) a long-term survival of 10%, at best. Immunotherapy has a role in the myeloid leukemias, and there is increasing evidence that of all hematopoietic neoplasms, CML may be the most susceptible to immune regulation. Roquinimex is known to enhance T cell, NK cell and macrophage activity. 
The use of autografting in chronic myelogenous leukemia (CML) remains controversial. Many reports suggest that intensive therapy for CML, with or without autologous transplantation, can restore Ph negativity and prolong life. [1] [2] [3] [4] [5] [6] However, most of these reports are small, and to date, no large clinical trials have demonstrated that ABMT in CML extends the duration of chronic phase or prolongs survival. An ongoing phase III study conducted jointly by the Medical Research Council of Great Britain and the Eastern Cooperative Oncology Group in the United States is currently evaluating this in a large multicenter trial (MRC CML IV, ECOG E7995). ABMT for CML has been performed using a variety of methods. 2, 5, 7, 8 Most of the early studies attempted to treat patients with CML in accelerated phase or frank blast crisis using prior cryopreserved cells obtained during the chronic phase. 7, [9] [10] [11] [12] [13] [14] In these reports either unmanipulated bone marrow or peripheral blood stem cells, or both, were used. Unmanipulated ABMT has also been used, with some success for patients in first chronic phase. 1, 14, 15 More recently, several centers have reported their experience of ABMT in CML using in vivo or in vitro manipulation of marrow designed to increase the overall response rate. 8, 16, 17 Some have exploited high-dose therapy in order to mobilize Ph-negative stem cells and use this as the source of the autograft. Together with this in vivo approach, which appears to be very promising, several in vitro manipulations have been attempted in order to reduce post-transplant relapses from 'contaminated' autografted leukemia cells. These include attempts to purge the marrow by long-term culture techniques, 18 direct purging with cytotoxic agents, 19 antibodies directed against the bcr-abl fusion protein 20 and the use of IFN-␥; 21 positive selection of CD34 ϩ DR Ϫ progenitors 22, 23 and the use of antisense oligonucleotides directed either against the bcl/abl oncogene or the myb gene. [24] [25] [26] It is now recognized that the efficacy of allogeneic BMT for acute or chronic myelogenous leukemia is only partially related to the conditioning regimen. Evidence for a graftversus-leukemia (GVL) effect is primarily based on the increased rate of relapse in recipients of syngeneic mar-row, 7 allogeneic marrow transplants without graft-versushost disease (GVHD), 27 and in most reports of T celldepleted donor transplants. 28 It was initially thought that T lymphocytes mediate both GVHD and GVL, with the two processes being independent. However, a large survey from the International Bone Marrow Transplant Registry (IBMTR) 29 reported that the relative risk for relapse for patients receiving T lymphocyte-depleted marrow transplants was greater than that observed for patients undergoing syngeneic transplants and both were significantly greater than the risk of relapse in patients undergoing undepleted allogeneic transplantation in whom GVHD did not develop. This suggests a T lymphocyte-mediated antileukemic effect that may be independent of GVHD or, at least, clinically apparent GVHD.
Due to the close association with GVHD and GVL it was originally thought that any beneficial effect of GVL could only be demonstrated in an allogeneic BMT setting. This idea posed a theoretical limitation to the efficacy of autografting in CML. In an attempt to overcome this limitation, efforts have recently been made to identify the effector cell, or cells, associated with GVL and to develop methods to induce the proliferation or reactivity in circumstances devoid of classic GVHD, such as ABMT. Several immunomodulating agents have been studied and are now undergoing clinical trials, mostly in acute myelogenous leukemia (AML). These include interleukin-2, 30 cyclosporin 31 and roquinimex. 32 There is increasing evidence that of all hematopoeitic neoplasms, CML may be the most susceptible to immune regulation. In allogeneic BMT, the effect of T cell-depleted grafts, or absence of GVHD, on relapse rate is greatest in CML patients. Additionally, patients who relapse after allogeneic BMT for CML have recently been shown to respond to infusions of donor T lymphocytes with complete reversal of all cytogenetic abnormalities. [33] [34] [35] [36] [37] [38] Roquinimex, a quinoline derivative, is an orally active novel immunomodulator that enhances T cell, NK cell, and monocyte/macrophage activity. [39] [40] [41] [42] In animal models, roquinimex has been associated with therapeutic effects in both primary tumors and metastases as well parasitic and viral infections. A pilot study in five patients with AML following ABMT demonstrated a significant increase in the classic NK immunophenotypes, CD16 ϩ /CD3 Ϫ and CD56 ϩ /CD3 Ϫ , concurrent with roquinimex administration. 43 Functional studies also indicated enhanced cytotoxic activity of patient cells against the NK-sensitive K562 cell line. Major randomized placebo controlled studies have just been completed in Europe, 16 North America and Australia evaluating the role of roquinimex in AML post ABMT. Owing to the immunological mechanisms inherent in CML, a phase II study was begun in 1992 at the University of Rochester, Rochester, New York, USA, to evaluate the role of roquinimex when given post ABMT to patients with CML. Very preliminary data on the first five patients have previously been described; 44 the updated data on all 17 patients are now reported.
Patients and methods
Patients eligible for this study were those aged 18-65 with Ph-positive CML at any stage of the disease, excluding blast crisis. Patients in CP2 were eligible as were those who had previously been treated with interferon. Those who had become cytogenetically negative following therapy with interferon were eligible for this study, provided their abnormal clone could be detected by molecular analysis using a panel of restriction enzymes and/or Southern blot analysis. Patients less than 45 years of age who had a histocompatible sibling, were excluded from this study. Using a modified Sokal score, 45 incorporating prognostic factors at presentation as well as the therapy given, for the 11 patients in CP1 the median prognostic score was 1.4 with a range of 0.78-1.9. Thus, five patients were in the low-risk group and six in an intermediate prognostic group. However, the fact that none of these patients ever had circulating erythroblasts, probably biases the score toward a more favorable prognostic range. The study was approved by the Human Investigations Committee of the University of Rochester, Rochester, New York and all patients signed informed consent. The study design is shown schematically in Table 1 . Following the conditioning regimen, unmanipulated bone marrow (usually Ͼ3 ϫ 10 8 NBC/kg body weight, but not less than 1 ϫ 10 8 NBC/kg body weight) or peripheral blood (at least Ͼ5 ϫ 10 8 NBC/kg or 1 ϫ 10 4 granulocyte-macrophage colony-forming unit (CFU-GM)/kg body weight) was to be infused as the source of stem cells. In fact, 16 patients received bone marrow stem cells alone; one patient also required peripheral stem cells due to the low number of cells obtained from the bone marrow. Following early engraftment (ANC Ͼ100/l), patients were treated with only roquinimex (Linomide, Pharmacia Upjohn, Kalamazoo, MI, USA) for up to 2 years as outlined in Table 1 . No other treatment for the CML was to be given with the roquinimex. An exception was one patient (described in detail later) who initially received roquinimex post ABMT for 4 weeks together with hydroxyurea and anagrelideuntil a complete hematological response was achieved.
The primary objective of the study was to determine the efficacy of the treatment regimen as measured by: (1) the rate and duration of cytogenetic conversions; (2) the time from BMT to clinical progression; and (3) overall survival from diagnosis and from bone marrow transplantation. A secondary objective was to determine the toxicity of roquinimex as administered in this study.
Between March 1992 and January 1995 17 patients entered the study and the data have been updated to August 1997. All patients were cytogenetically positive for the Ph 46 and were then reinfused with marrow obtained in the CP2 as the source of stem cells. The four patients in AP were reinfused with marrow obtained during the accelerated phase. The median age of the patients was 48 years (range 12-56 years) and the median time from diagnosis to ABMT was 33 months (8-37). The median time to engraftment of neutrophils to 500/l was 15 days (range 7-165 days).
Results

Transplant course and survival
All patients tolerated the transplant fairly well with no procedural mortality. The usual peritransplant morbidities consisted mostly of neutropenic fever with sepsis and one patient suffered from diffuse alveolar hemorrhage from which she fully recovered.
Post transplantation, nine patients have died; eight of progressive disease. Two patients transplanted in CP2 died at 5 and 60 months post BMT; three patients transplanted in AP at 10, 13 and 28 months and three transplanted in CP1 at 20, 25 and 40 months. One patient died 33 months after BMT -in complete cytogenetic and molecular remission -from AIDS acquired from a platelet transfusion given in the post-transplant period.
Toxicity from roquinimex
During the 2-year span of roquinimex administration virtually all patients had some form of edema and approximately half of the patients complained of severe musculoskeletal discomfort requiring analgesia. Eleven patients demonstrated skin changes -six patients had a skin biopsy that was typical of graft-versus-host disease with lymphocytic infiltrate and exocytosis, and 10 patients exhibited eccrine sweat gland necrosis. One patient experienced severe hypothyroidism and another a pleural effusion ( Table 2 ). All these toxicities resolved following withdrawal of roquinimex. 
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Ph positive Ph negative Figure 1 Cytogenetic response for patients transplanted in first chronic phase. All patients were reinfused with 100% Ph-positive marrow. The only medication post transplant was roquinimex.
Cytogenetic response
The cytogenetic data are illustrated in Figure 1 , which summarizes the response following transplant for the patients in CP1. Of the 11 patients, nine had at least a transient cytogenetic response at some time post transplant. Most importantly, five had a complete cytogenetic response, that is 100% Ph-negative metaphases at 1 year or beyond, and seven of the 11 patients had a major response -greater than 65% Ph-negative metaphases -at 1 year or beyond. Furthermore, four of the 11 patients had a complete cytogenetic response (100% Ph negative) at 2 years or beyond.
It is important to note that all these patients started as 100% Ph positive and were reinfused, following busulfan and cyclophosphamide conditioning, with marrow containing unmanipulated Ph-positive cells. Figure 2 describes the cytogenetic responses of patients in more advanced disease; there were far fewer responses in this patient group. Figure 3 summarizes the clinical response of patients in first chronic phase. All CP1 patients had a hematological response following transplantation for at least 1 year and nine of the 11 had a hematological response for over 2 years. For the purpose of this report, a complete hematological response is defined as a sustained white cell count of less than 10 000/l without any therapy for the CML, except for roquinimex. A complete hematologic response is defined as a sustained white cell count of less than 10 000/l without any therapy for the CML, except for roquinimex.
Clinical and hematological response
Accelerated phase
Second chronic phase more advanced disease and shows something that is not so evident looking only at the cytogenetic data. For example, the first patient was a 49-year-old woman who had an aggressive AP prior to transplant. She recovered from the ABMT in chronic phase with high blood counts and required anagrelide and hydroxyurea to maintain her blood counts. She then, on roqinimex, within 4 weeks, went into a complete hematological response and the anagrelide and hydroxyurea were discontinued; after several months she developed what looked very much like graft-versus-host disease as well as bone marrow aplasia which was thus thought to be immunologic in etiology. Roquinimex was discontinued and her blood counts recovered without any therapy. Approximately 1 year later she went into frank blast crisis at which point she was treated again with roquinimex only, provided on a compassionate basis. She had a complete but brief hematologic response to the roquinimex before she again went into blast crisis, from which she ultimately died.
The third patient, whose course is outlined in Figure 4 , is a young man who was transplanted in AP and although cytogenetically Ph positive he is now 27 months from the transplant with no specific therapy for his CML other than the 24 months of roquinimex. Perhaps the most interesting patient is the first one in second chronic phase (Figure 4 ) who presented with blast crisis and was induced with intenstive chemotherapy 46 back into CP2 requiring high-dose hydroxyurea to maintain her in second chronic phase. Her bone marrow was harvested in very active CP2 and she was then autotransplanted. She initially had a complete hematological response for 6 months and for the first time a proportion of Ph-negative metaphases were seen in her marrow. She then continued for almost 4 years in very stable chronic phase before accelerating again.
Figures 5 and 6 reflect the survival of patients from diagnosis and ABMT, respectively. Table 3 describes the immunophenotypic results among the patients receiving this protocol therapy. Values given are the means for all patients at particular time points.
Discussion
The use of autologous transplantation in CML remains controversial. There are now sufficient data that support the concept that normal Ph-negative hematopoietic progenitors are present in the marrow of at least, some patients with CML. [47] [48] [49] [50] Most recent efforts have been directed at making some attempt to alter the degree of Ph positivity in the reinfused graft. [16] [17] [18] [19] The fact that this has not resulted in major improvement compared with the use of unmanipulated grafts is not completely surprising. The preponderance of the data now suggest that the immunologic mechanisms inherent in graft-versus-leukemia are primarily responsible (11) 96 (10) 33 (3) 89 (6) 152 (7) 460 (13) CD56 ϩ NK 52 (3) 44 (13) 81 (8) 32 (3) 95 (6) 129 (6) 402 (8) CD57 ϩ NK 20 (1) 12 (4) 26 (3) 10 (1) 19 (1) 48 (3) 309 (4) all CD57 ϩ 124 (11) 72 (19) 318 (28) 273 (24) 340 (23) 510 (25) 997 (26) CD20 ϩ B
345 (11) 3 (1) 14 (2) 64 (5) 123 (9) 266 (16) 176 (13) CD4 ϩ 817 (35) 120 (44) 220 (30) 292 (25) 416 (34) 422 (24) 836 (23) CD8 ϩ 476 (25) 155 (39) 618 (57) 548 (44) 586 (42) 641 (36) for the curative results following allogeneic bone marrow transplantation, and without graft-versus-leukemia over 50% of patients relapse. Thus, infusing a cell population that may be primarily Ph negative may not, in and of itself, significantly affect the ability of the conditioning regimen to eradicate the leukemia. The method described in this report uses unmanipulated Ph-positive marrow as the source of the reinfused stem cells but attempts to induce an immunologic response in patients post transplant. The mechanisms of action of roquinimex in this study are far from clear. Although there are data for AML patients that suggest a significant increase in NK and T cells post roquinimex, 43 the immunophenotypic profile in Table 3 cannot confirm this in this patient population. However, these data are impossible to interpret without an adequate control group. Ideal patients for such a control group would be CML patients autografted without receiving roquinimex. Such patients were not available in this small pilot phase II study and comparing these data to immunologic data obtained from patients autografted for other diseases would be problematic. Furthermore, the apparent lack of an increase of NK cells (CD16 ϩ /CD3 Ϫ ; CD56 ϩ /CD3 Ϫ ) needs to be very cautiously assessed. Since there appears to be a deficiency of NK cells in patients with CML, 51, 52 a more accurate measure may be a normalization of NK cell number and function following roquinimex therapy. Additionally, functional studies of NK cell subsets need to be performed in the future for more accurate assessment of the enhancement of natural killer cell function. Looking at this immunophenotypic profile, there is no ready explanation for the persistently low CD20 ϩ B cell population. It is also noted that the CD4/CD8 ratio remains persistently low post transplant for up to 24 months on roquinimex. Again, comparable data are not available for CML patients autografted after busulfan-cyclophosphamide conditioning with no immunologic modulation post transplant.
The presence of skin changes that appeared identical to typical graft-versus-host disease strongly suggest an immunological mechanism. This incidence is much higher than the rate of spontaneous autologous graft-versus-host response without immunotherapy (less than 10%). The uniformity of the musculoskeletal aches and peripheral edema are also intriguing in this patient population receiving roquinimex. While these are known side-effects of roquinimex, the frequency in patients with CML is far greater than observed in the two large studies of roquinimex in patients with AML, using identical doses of roquinimex, 16, 53 suggesting perhaps an immune modulation inherent to the biology of CML. 54 The hypothyroidism and pleural effusion, each noted in one patient in this study, may also have had an immune basis, and pericarditis has been noted with roquinimex use in other situations.
Cytogenetic responses in this study were in excess of what one would expect using unmanipulated stem cells as the source of a graft. 55 While a significant percentage of patients may recover following unmanipulated stem cell autografts with a Ph-negative clone, this is usually shortlived and within less than 12 months most patients revert to complete Ph positivity. 55, 56 The seven of 11 patients in CP1 who had a major cytogenetic response (at least 65% Ph negativity) as well as the five complete cytogenetic responders at 1 year and four complete cytogenetic responders at 2 years, attest to the potential that this drug may have in CML post autotransplantation. A closer look at Figure 1 indicates that at least in some of the patients the cytogenetic response developed over time and did not simply represent engraftment with a Ph clone. This can be clearly seen in patients 2, 4, 5, 6, 8 and 11. Essentially, nine out of 11 patients in first chronic phase had a cytogenetic response at some time post ABMT. The two patients who had no cytogenetic response at any time (patients 7 and 10) were heavily pretreated pretransplant. It is probably not reasonable to expect all patients to have the inherent capacity to exhibit a cytogenetic response following autologous transplantation. This would be true if they did not have any pre-existing bcr/abl-negative primitive progenitor cells to reconstitute hematopoiesis post transplantation. Some patients with advanced CP1 may not have such cells and no mechanism could produce a cytogenetic response in this patient population. 56, 57 This is also likely to explain the small number of expected cytogenetic responses in patients in AP or CP2 at time of stem cell reinfusion.
Virtually all patients had a hematological response post transplant. Figure 3 demonstrates that none of the 11 patients in CP1 required any form of therapy for the first year post transplant, while on roquinimex. Figure 3 further demonstrates the reversion to second chronic phase in a significant number of patients after the cessation of the roquinimex therapy, as per protocol, at 2 years. It is possible that for a more durable response, roquinimex needs to be continued indefinitely or at least for considerably longer periods -much like current therapy with ␣-interferon at time of diagnosis with CP CML. 49 The overall survival from transplant, and from diagnosis, (Figures 5 and 6 ) needs to be very cautiously interpreted in the absence of a suitable control group. Furthermore, these numbers are too small to suggest any conclusions regarding overall survival. 3, 5 It is likely that other manipulations pre-or post transplant may enhance the results for this patient group. The purpose of this study design was to demonstrate the activity of roquinimex in CML after a state of minimal residual disease had been achieved. This could only be demonstrated in the absence of any other concurrent manipulation. These data do not suggest that roquinimex may be curative in CML post transplant. However, the data are at least as encouraging as the early data using interferon therapy and suggest that in future roquinimex may be added to standard therapy with CML, either post autografting to maintain minimal disease state or without autografting, in an attempt to prolong both disease-free and overall survival. Whether autologous transplantation has curative potential for patients with CML has yet to be determined as does its potential to improve duration of chronic phase or survival in this disease. Given the preliminary limited experience with autografting in this disease and the failures due to relapse in all autograft settings, attempts to preserve or eradicate states of minimal disease will most certainly be required. The patients described in this study suggest that roqunimex may have potential to modulate CML post autografting. Further studies will be required to elucidate its mechanism of action and potential role in this setting.
